period, the cells were transferred to medium lacking PMA. The cells were first tested for ERK activation in response to PMA after~1 month. Wild-type (WT) and NV cells were regularly evaluated for phenotype by measuring ERK activation in response to PMA (see below). In all of the experiments shown, NV cells showed no PMA responsiveness by this assay.
Cell proliferation and viability assays EL4 cells were cultured in complete culture medium to which various agents were added. PMA, 4α-PMA, thymeleatoxin, mezerein, indolactam V, prostratin (12-deoxyphorbol-13-acetate), phorbol 12-tigliate-13-decanoate and 4-Omethyl PMA were from LC Services. Bryostatin 5 was provided by Dr Khapil Bhalla (MUSC). PD 098059 was obtained from Calbiochem. At various times after treatment, cell density and viability (trypan blue exclusion) were determined using a hemacytometer. Cells were photographed using a Nikon Diaphot microscope with Hoffman interference optics (ϫ20 objective). Fig. 1 . Effects of PKC activators on viability and density of WT and NV Interleukin-2 assays EL4 cells. WT and NV cells were incubated for 20 h in complete medium IL-2 secretion was measured either by bioassay or using an ELISA method. containing 100 nM PMA, 100 nM 4αPMA, or 1 µM thymeleatoxin. In For the bioassay, culture supernatant harvested from cells treated with various panel (A) cell viability is expressed as the percent of the cell population agents for 20-24 h was added to CTLL, an IL-2 dependent T-cell line. After excluding trypan blue. In panel (B) cell density (cells/ml) is expressed as a 48 h, [ 3 H]thymidine was added. Thymidine incorporation was assessed 24 h percent of the density of untreated ('control') cells. For both panels, each later, as previously described (23) . A standard curve was generated by adding data point represents the mean Ϯ SEM of values obtained from two recombinant IL-2 to CTLL cells in the same assay. ELISA assays for murine separate experiments. IL-2 in the culture supernatant were carried out using reagents obtained from BioSource International.
Protein kinase assays
decanoate (100 nM). PMA is a strong tumor promoter, 4αPMA is an inactive isomer of PMA, and the remaining compounds ERK and RSK activities were measured in cytosolic extracts as previously described (5, 24) , using myelin basic protein (MBP) and S6 peptide are weak or incomplete tumor promoters. The PKC activators (RRLSSLRA; S6P) as substrates for ERK and RSK, respectively. JNK assays used were able to elicit maximal ERK activation in WT cells were performed using whole-cell extracts with GST-c-Jun bound to glutathioneat the concentrations used (see below). Results are shown only Sepharose as substrate.
for selected compounds. PMA and thymeleatoxin were toxic
Immunoblotting and immunoprecipitation
to WT cells while 4αPMA was not ( Figure 1A) . Viability of Cytosolic cell extracts were prepared as for the ERK assay (4). Whole cell NV cells was not reduced by any of the compounds tested. In extracts were prepared similarly, but without sonication, in buffer containing Figure 1B , cell density (cells/ml) represents that attained by 20 mM HEPES (pH 7.4), 1% Triton X-100, 50 mM NaCl, 1 mM EGTA, 5 mM β-glycerophosphate, 30 mM sodium pyrophosphate, 100 µM sodium proliferation during the 20-h incubation. Proliferation was orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, and inhibited in WT cells incubated with PMA or thymeleatoxin, 10 µg/ml leupeptin. Proteins were separated by SDSϪPAGE on 10 or 12.5% as compared with the control of 4αPMA-incubated cells. This Laemmli gels, transferred to PVDF, incubated with primary antibodies, and result is consistent with PMA-induced cell cycle arrest noted developed using a gold-labeled secondary antibody with silver enhancement (Amersham). Antibody sources were: ERK (pan-ERK), Transduction Labs; previously in these cells (25, 26 The effects of PMA on growth of the WT and NV cells The phorbol ester-resistant EL4 cells characterized previously in our laboratory were unable to activate ERKs in response to were examined. Cells were incubated overnight with PMA and other PKC activators. Cell viability was assessed by PMA (4, 5) . As shown in Figure 3 , ERKs were activated in response to PMA in WT but not NV cells. The inactive phorbol trypan blue exclusion, while proliferation was assessed by cell counts. The compounds tested were: PMA (100 nM), ester, 4αPMA, had no effect on ERK activity. All other PKC activators tested caused ERK activation, with no consistent 4αPMA (100 nM), thymeleatoxin (1 µM), mezerein (1 µM), bryostatin 5 (100 nM), indolactam V, 4-O-methyl-PMA differences in time course or magnitude of response in a 60-min incubation. The concentrations of the activators used (100 nM), prostratin (100 nM), and phorbol 12-tigliate 13- throughout this study were chosen on the basis of their ability 
experiments (data not shown). None of the compounds tested
Cells were photographed using Hoffman interference optics.
activated ERKs in NV cells (Figure 3) .
In previous studies, we have shown that PMA-resistant EL4 cells can activate MEK and ERK in response to okadaic acid (OA), a protein phosphatase inhibitor that does not activate PKCs (4, 5) . Incubation with 10 µM OA for 10 min resulted in activation of ERK and RSK in both WT and NV cells, as detected using in vitro assays for kinase activity (ERK: 450% of control in WT, 206% of control in NV). The NV cells appeared less sensitive to OA than the original variant cells. This point is reinforced in Figure 3 . When cells were treated for various times with a low dose of OA (1 µM), a gradual activation of ERKs was seen only in WT and not in NV cells.
An alternative method for examining activation of ERKs is to examine their phosphorylation state. When whole-cell extracts of control and PMA-treated WT and NV cells were immunoblotted using an antibody that recognizes ERK-1/ ERK-2, both ERK1 and ERK2 showed shifts in electrophoretic mobility on SDSϪPAGE in extracts from PMA-treated WT cells (24). Such shifts are correlated with activating phosphorylations of ERKs (27). Shifts in ERK mobility were not observed in NV cells treated with PMA ( Figure 4A ). Immunoblots using an anti-active-ERK (dually phosphorylated ERK) antibody confirmed that ERKs were activated by PMA in WT, but not NV cells ( Figure 4A ). ERK mobility shifts were seen in cytosol from WT cells treated with PMA, Equal amounts of cytosolic protein were separated on SDSϪPAGE and immunoblotted using antibodies to the indicated isoforms of PKC. All samples were obtained in the same experiment and analyzed in parallel. (B) WT and NV EL4 cells were incubated for 10 min in the absence ('C') and presence ('P') of 100 nM PMA. Cytosolic and membrane fractions were prepared. Equal amounts of protein were separated on SDSϪPAGE and immunoblotted for PKCs α and η. All samples were obtained in the same experiment and analyzed in parallel. (C) WT EL4 cells were incubated for the indicated times with 100 nM 4αPMA, 100 nM bryostatin 5 or 1 µM mezerein. Cytosolic and membrane fractions were prepared. Equal amounts of protein were separated by SDSϪPAGE and immunoblotted for PKCη. study are shown in Figure 4B . While a dose-dependent 100 nM PMA caused rapid translocation of PKCη from cytosol to membrane in both WT and NV cells. This response is most inhibition of ERK phosphorylation was observed, complete inhibition was not observed at the highest dose of PD 098059 readily seen by changes in cytosolic PKCη. Similar results were seen for PKCα ( Figure 5B ) and PKCθ (data not shown). used (50 µM). It was not possible to use higher doses, because of the limited solubility of the drug at 50 µM (29). Quantitative Bryostatin 5 and mezerein, but not 4αPMA, likewise caused translocation of PKCη from cytosol to membranes in WT cells results, obtained by measuring MBP kinase activity in cytosolic extracts, showed that 20 µM PD 098059 inhibited PMAwithin 5 min ( Figure 5C ). Similar results were seen for all other PKC activators used (data not shown), suggesting that induced ERK activation by 41%. This incomplete inhibition is consistent with a report that PD 098059 does not completely multiple PKC activators can activate PKCη in EL4 cells.
Compounds that activate PKC can induce down-regulation inhibit ERK activation in response to PMA or high doses of growth factors (29).
of some PKC isoforms. PKCα was severely depleted from both cytosolic and membrane fractions following a 20-h Expression and translocation of PKC isoforms in WT and incubation with PMA ( Figure 6 ). For PKCs η and θ, cytosolic NV cells and total levels remained depressed after 20 h. Thus, PMA The mechanisms underlying PMA responsiveness were further treatment causes down-regulation of three different PKC isoexplored. Since PMA exerts its effects via binding to PKC forms in WT EL4 cells. isoforms, immunoblotting was utilized to examine the expresOverexpression of PKCη in EL4 cells sion and localization of these target proteins. Expression of PKCs α, ε, η, θ and ζ was detected in both WT and NV cells.
The results described above suggested that expression levels of PKCs η or α might be important in modulating PMA Results are shown in Figure 5A for α, ε, η and θ. In this experiment, levels of η and α were significantly reduced in sensitivity. Underexpression of PKCη in NV cells was a consistent finding, while relative levels of expression of PKCα NV cells, while levels of θ were similar between the two cell lines. PKCε was detected at such low levels that comparison were sometimes similar between WT and NV cells (data not shown). We examined whether enhanced expression of PKCη between cell lines was compromised. As shown in Figure 5B , synergistic manner by a combination of PMA and calcium might restore PMA sensitivity. NV cells were transiently ionophore (8) . JNK activity was assessed following affinity transfected with an expression vector for PKCη. As shown in purification of the kinases on a solid-phase substrate. JNK Figure 7A , transfected cells showed an increase in expression activity was slightly increased in response to PMA alone in of PKCη that was correlated with the amount of DNA WT cells ( Figure 8A ), as previously reported (24), and was transfected. However, the transfected cells did not activate synergistically activated with co-stimulation by PMA plus ERKs in response to PMA ( Figure 7B ). PMA-induced activaionomycin. In NV cells, JNKs were slightly activated in tion of RSK was likewise not observed in PKCη-transfected response to ionomycin, but not to PMA; a combination of NV cells ( Figure 7C ). Similar negative results were obtained PMA and ionomycin produced no further increase. Activation with PKCα transfections, either with or without co-transfection by PMA and ionomycin in WT cells was maximal by 20 min, of PKCη (data not shown). To test whether the number of and activity declined to basal levels by 90 min ( Figure 8B ). transfected cells was sufficient, immunolocalization of PKCη
The effects of other PKC activators were examined. Bryostawas performed (data not shown). The results confirmed that tin activated JNK in a calcium-dependent manner at 10 min, expression of PKCη was lower in NV than in WT cells.
but to a lesser extent than PMA ( Figure 8C ). Thymeleatoxin Following transfection of NV cells with DNA encoding PKCη, induced little or no JNK activation at 10 min. Some stimuli at least 15% of the cells expressed high levels of PKCη. Any induce delayed and/or prolonged JNK activation (30) . Activarestoration of PMA-induced ERK activation should have been tion of JNKs was not observed in response to PMA, mezerein detectable, since ERK activation was detected when a mixture or thymeleatoxin alone, or to mezerein or thymeleatoxin with of 85% NV/15% WT cells was incubated with PMA (data not ionomycin, at up to 120 min (data not shown). shown). Thus, enhanced expression of PKCη is not sufficient to restore PMA responsiveness.
Effects of PKC activators on IL-2 synthesis Effects of PKC activators on JNK activity
PMA-resistant EL4 cell lines have previously been shown to be deficient in production of IL-2 in response to PMA (1). ILJNKs have been implicated as an important mediator of IL-2 2 secretion was examined using a bioassay for IL-2 (Figure expression in T-cells, and are activated in other cell types by 9A). WT cells secreted IL-2 in response to PMA, while NV agents that induce programmed cell death (10) . JNKs can be weakly activated by PMA alone, but are activated in a cells did not. OA did not increase IL-2 synthesis in either cell tion nor IL-2 expression was required for PMA-induced toxicity in EL4 cells. The role of ERK activation was therefore examined. WT cells were incubated in complete culture line, indicating that ERK activation is not sufficient to induce IL-2 synthesis. medium in the absence and presence of 100 nM PMA with or without 20 µM PD 098059. Cell viability ( Figure 10A ) and The IL-2 studies were extended to other PKC activators, using an immunoassay for murine IL-2 ( Figure 9B ). WT cells proliferation ( Figure 10B ) were assessed at various times following PMA addition. The doubling time of untreated cells secreted IL-2 in response to PMA. Ionomycin did not enhance the response to PMA. NV cells did not produce IL-2 in was approximately 20 h. PMA alone inhibited proliferation and reduced viability, consistent with the results shown earlier response to PMA, with or without ionomycin (data not shown). Phorbol 12-tigliate 13-decanoate, indolactam V, mezerein and in Figure 1 . PD 098059 alone caused a slight decrease in viability (at~20 h) and proliferation (after 20 h). However, thymeleatoxin induced IL-2 synthesis when added alone, with levels of IL-2 similar to those seen in response to PMA.
PD 098059 completely blocked the ability of PMA to inhibit both proliferation and viability. PD 098059 also inhibited the Responses to mezerein and thymeleatoxin were slightly effects of PMA on cell morphology ( Figure 10C) PKCη responds to PKC activators in both cell types. The role of PKCη in T-lymphocyte signaling has not been established.
Discussion
PKCη, a major isoform in mouse skin (36), is down-regulated in mouse epidermis in response to application of PMA (37) . In this study, we have examined the effects of a variety of PKC activators on phorbol ester-sensitive and -resistant EL4
In a leukemia cell line with the multidrug resistance phenotype, originally selected for resistance to okadaic acid, PMA toxicity thymoma cells. In the sensitive (WT) cell line, treatment with PMA activates the ERK phosphorylation cascade. This is retained despite underexpression of PKCε (38 Alternatively, the possibility that MEK is involved in ERKindependent signaling pathways has recently been raised (40) . induced IL-2 synthesis. These data indicate that pathways in addition to ERK and JNK are required for IL-2 synthesis, and
In a recently-published study of the mechanism of PMAinduced cell death in EL4 cells, Desrivieres and co-workers that PKC activators can differ in their abilities to stimulate these pathways.
concluded that PMA induced cell cycle arrest was not mediated by MEK/ERKs (26) . These investigators showed that PD Our results indicate that various PKC activators do not discriminate between calcium-dependent and -independent 098059 partially inhibited PMA-induced ERK activation, but did not inhibit the reduction in [ 3 H]thymidine incorporation PKC isoforms in EL4 cells. Similar conclusions have been reached by other investigators for some of these compounds observed after a 6-h incubation with PMA. The differences in the conclusions drawn between this study and our own may (31) (32) (33) (34) . All of the compounds tested caused similar responses in terms of cell toxicity, ERK activation and translocation of arise from differences in the protocols used to assess cell proliferation and viability. In our study, the ability of PD PKCη, a calcium-independent isoform. The abilities of PKC activators to show isoform selectivity in some cell types, but 098059 to block PMA-induced cytotoxicity was most apparent after 20 h of incubation. It is thus possible that the late phases not in others, likely reflects aspects of PKC regulation that have not yet been fully defined (e.g. phosphorylation of PKC, of the response to PMA are most dependent on MEK/ERK activation. interaction of PKC with docking proteins). The responses observed in WT EL4 cells were independent of the abilities The molecular mechanism responsible for coupling PKC activation to ERK or JNK activation has not been completely of the compounds to act as complete or incomplete tumor promoters in mouse skin. For example, 4-O-methyl-PMA, established in any cell type. While differences in signal transduction between PMA-sensitive and resistant EL4 cells which causes proliferation but not tumor promotion in mouse skin (35) , activated PKCs and ERKs in EL4 cells with a remain to be explored, our observations point to potential roles for alterations in ERK signaling pathways in mediating phorbol potency similar to that of PMA. This compound was previously shown to be much less potent than PMA as a proliferative ester toxicity in T-lymphocytes. agent in mouse skin (35 
